Melanoma Clinical Trial
Official title:
Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD4+ NY-ESO-1-Specific T Cells and Anti-CTLA4 For Patients With NY-ESO-1-Expressing Tumors
The goal of this clinical research study is to learn about the safety of giving CD4+T cells
with ipilimumab and cyclophosphamide.
CD4+T cells are a type of white blood cell. Researchers grow the T cells in the laboratory,
and they are designed to find cancer cells and may kill them.
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a study
group based on when you join this study. The first 3 or 6 participants will receive a lower
dose of ipilimumab. If there are no intolerable side effects, then the second group of 6
participants will receive a higher dose of ipilimumab.
All study participants will receive the same dose level of cyclophosphamide and the CD4+T
cells.
Study Drug Administration:
You will receive cyclophosphamide by vein over about 30-60 minutes on Day -2 (2 days before
you receive the CD4+T cells). If the doctor thinks it is needed, you will be given standard
drugs to help decrease the risk of side effects. You may ask the study staff for information
about how the drugs are given and their risks.
On Day 0, you will receive the CD4+T cells by vein over about 30-60 minutes. You will stay in
the hospital overnight after the dose.
On Days 1, 22, 43, and 64, you will receive ipilimumab by vein over about 90 minutes.
Study Visits:
Within 2-4 weeks before you receive the CD4+T cells:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests, immune system tests, and
tests on how long the T-cells survive in your body.
- You will have a computed tomography (CT) scan or x-rays to check the status of the
disease.
On Day -2:
- You will have a physical exam.
- Blood (about 1 tablespoon) will be drawn for routine tests. This routine blood draw will
include a pregnancy test if you can become pregnant.
On Day 1:
- You will have a physical exam.
- Blood (about 1 tablespoon) will be drawn for routine tests.
On Days 0, 7, 14, 22, 28, 35, 43, 49, and 56:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests, immune system tests, and
tests on how long the T-cells survive in your body.
On Day 3, blood (about 5½ tablespoons) will be drawn for routine tests, immune system tests,
and tests on how long the T-cells survive in your body.
Between Day 35 and 42 and again between Day 77 and 84, you will have a CT scan or x-rays to
check the status of the disease.
The study tests may be repeated or you may have additional tests performed anytime the doctor
thinks it is needed.
Some of the study tests may be done at your local clinic if you cannot return to MD Anderson.
The study staff will discuss this with you.
Length of Study Drug Dosing:
Your last study drug dose will be on Day 64. You will no longer be able to take the study
drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to
follow study directions.
Your participation on the study will be over after the follow-up.
End-of-Study-Drug-Dosing Visit:
On Day 64:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests, immune system tests, and
tests on how long the T-cells survive in your body.
Follow-Up:
On Days 70, 77, 84, 105, 126, 147, and 168:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests, immune system tests, and
tests on how long the T-cells survive in your body.
Every 3 months after Day 84, unless the disease gets worse or you start another cancer
therapy, you will have a CT scan or x-rays to check the status of the disease. Every 3 months
for up to 5 years, the study staff will call you or ask your doctor how you are doing. If you
are called, the calls should last about 10-15 minutes.
If the doctor thinks it is needed to confirm the status of the disease, blood (about 1½
tablespoons) will be drawn every 3 months for up to 1 year.
If the doctor thinks it is needed, you will return to the clinic every 4-6 weeks starting
after Day 168 or as often as the doctor thinks is needed. These visits will stop if the
T-cells disappear or if the disease gets worse. Blood (about 5½ tablespoons) will be drawn
for routine tests, immune system tests, and tests on how long the T-cells survive in your
body.
This is an investigational study. CD4+T cells are not FDA approved or commercially available.
They are currently being used for research purposes only. Cyclophosphamide is FDA approved
and commercially available for the way it is being used in this study. Ipilimumab is FDA
approved and commercially available for the treatment of melanoma, but not for sarcoma. The
study doctor can explain how the study drugs are designed to work.
Up to 12 participants will be enrolled in this study. All will take part at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|